$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000143774923007710 Filed on March 24, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$17.19M	$18.09M	$64.36M
YoY Change	26.75%	11.86%	33.96%
Cost Of Revenue	$2.265M	$2.263M	$7.654M
YoY Change	48.52%	42.42%	48.42%
Gross Profit	$14.93M	$15.83M	$56.70M
YoY Change	23.99%	8.53%	32.22%
Gross Profit Margin	86.83%	87.49%	88.11%
Selling, General & Admin	$24.47M	$21.63M	$82.84M
YoY Change	14.9%	1.01%	-5.37%
% of Gross Profit	163.96%	136.67%	146.09%
Research & Development	$12.50M	$14.48M	$52.91M
YoY Change	-1.56%	10.66%	11.05%
% of Gross Profit	83.73%	91.46%	93.3%
Depreciation & Amortization	$200.0K	$236.0K	$900.0K
YoY Change	0.0%	10.8%	12.5%
% of Gross Profit	1.34%	1.49%	1.59%
Operating Expenses	$36.97M	$36.11M	$135.7M
YoY Change	8.75%	4.67%	0.42%
Operating Profit	-$22.05M	-$20.28M	-$79.04M
YoY Change	0.4%	1.84%	-14.36%
Interest Expense	-$2.908M	-$2.817M	-$7.428M
YoY Change	938.57%	-14185.0%	-2135.07%
% of Operating Profit
Other Income/Expense, Net	-$15.00K	-$5.081M	-$21.56M
YoY Change	-99.74%	-31.52%	23.59%
Pretax Income	-$30.19M	-$28.18M	-$108.0M
YoY Change	7.57%	3.17%	-1.23%
Income Tax	$21.00K	$69.00K	$1.135M
% Of Pretax Income
Net Earnings	-$30.21M	-$28.25M	-$109.2M
YoY Change	6.41%	-0.71%	-1.5%
Net Earnings / Revenue	-175.74%	-156.14%	-169.62%
Basic Earnings Per Share	-$1.30		-$4.81
Diluted Earnings Per Share	-$1.30	-$1.22	-$4.79
COMMON SHARES
Basic Shares Outstanding	23.44M	23.09M	22.81M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.05M	$99.96M	$99.96M
YoY Change	-52.32%	12.14%	12.14%
Cash & Equivalents	$36.54M	$55.41M	$55.41M
Short-Term Investments	$28.51M	$44.56M	$44.56M
Other Short-Term Assets	$12.96M	$11.91M	$11.91M
YoY Change	31.91%	36.91%	36.91%
Inventory	$5.466M	$4.325M	$4.325M
Prepaid Expenses
Receivables	$12.49M	$12.70M	$12.70M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$95.97M	$128.9M	$128.9M
YoY Change	-40.21%	12.69%	12.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.103M	$1.297M	$3.749M
YoY Change	-37.93%	-34.06%	19.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.17M	$0.00	$0.00
YoY Change	1408.16%	-100.0%	-100.0%
Other Assets	$3.160M	$2.740M	$2.963M
YoY Change	101.02%	109.0%	93.16%
Total Long-Term Assets	$16.98M	$6.712M	$6.712M
YoY Change	227.12%	25.32%	25.32%
TOTAL ASSETS
Total Short-Term Assets	$95.97M	$128.9M	$128.9M
Total Long-Term Assets	$16.98M	$6.712M	$6.712M
Total Assets	$113.0M	$135.6M	$135.6M
YoY Change	-31.84%	13.26%	13.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.968M	$5.527M	$5.527M
YoY Change	64.57%	-4.48%	-4.48%
Accrued Expenses	$16.05M	$16.05M	$16.05M
YoY Change	36.26%	11.85%	11.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.23M	$23.92M	$23.92M
YoY Change	32.18%	6.86%	6.86%
LONG-TERM LIABILITIES
Long-Term Debt	$97.94M	$97.54M	$97.54M
YoY Change	38.34%
Other Long-Term Liabilities	$106.3M	$103.5M	$103.5M
YoY Change	14.46%	16.38%	16.38%
Total Long-Term Liabilities	$97.94M	$97.54M	$201.1M
YoY Change	38.34%		126.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.23M	$23.92M	$23.92M
Total Long-Term Liabilities	$97.94M	$97.54M	$201.1M
Total Liabilities	$229.5M	$225.0M	$225.0M
YoY Change	25.56%	102.08%	102.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$607.3M	-$577.1M
YoY Change	22.51%	23.5%
Common Stock	$490.8M	$487.9M
YoY Change	2.53%	2.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$116.6M	-$89.36M	-$89.36M
YoY Change
Total Liabilities & Shareholders Equity	$113.0M	$135.6M	$135.6M
YoY Change	-31.84%	13.26%	13.26%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$30.21M	-$28.25M	-$109.2M
YoY Change	6.41%	-0.71%	-1.5%
Depreciation, Depletion And Amortization	$200.0K	$236.0K	$900.0K
YoY Change	0.0%	10.8%	12.5%
Cash From Operating Activities	-$25.81M	-$21.75M	-$87.56M
YoY Change	7.55%	8.38%	3.14%
INVESTING ACTIVITIES
Capital Expenditures	$23.00K	$13.00K	$254.0K
YoY Change	-8.0%	-106.44%	-66.22%
Acquisitions
YoY Change
Other Investing Activities	$6.293M	$23.12M	$1.314M
YoY Change	-53.8%	147.89%	-72.74%
Cash From Investing Activities	$6.270M	$23.11M	$1.060M
YoY Change	-53.88%	153.24%	-73.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$671.0K	25.37M	$97.13M
YoY Change	-99.05%	-79375.0%	34.31%
NET CHANGE
Cash From Operating Activities	-$25.81M	-21.75M	-$87.56M
Cash From Investing Activities	$6.270M	23.11M	$1.060M
Cash From Financing Activities	$671.0K	25.37M	$97.13M
Net Change In Cash	-$18.87M	26.72M	$10.64M
YoY Change	-131.27%	-343.45%	-225.06%
FREE CASH FLOW
Cash From Operating Activities	-$25.81M	-$21.75M	-$87.56M
Capital Expenditures	$23.00K	$13.00K	$254.0K
Free Cash Flow	-$25.83M	-$21.76M	-$87.81M
YoY Change	7.53%	9.55%	2.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23129953
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23129953
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22462995
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22462995
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	96355000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110820000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1511000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38079
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
CY2022	dei	City Area Code CityAreaCode	646
CY2022	dei	Local Phone Number LocalPhoneNumber	768-9780
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
CY2022	dei	Trading Symbol TradingSymbol	URGN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	145100000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23440521
CY2022	dei	Auditor Firm AuditorFirmId	238
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022	dei	Auditor Location AuditorLocation	Florham Park, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55408000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44360000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44556000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44779000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	813000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1226000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12704000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11717000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4325000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4832000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11101000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7476000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	128907000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	114390000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	675000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2740000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1311000	usd
CY2022Q4	us-gaap	Assets Assets	135619000	usd
CY2021Q4	us-gaap	Assets Assets	119746000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8257000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6948000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3276000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3330000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23916000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22380000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97537000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3018000	usd
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2842000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	224980000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	111333000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	61000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	487787000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	475698000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577104000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467321000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-107000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	135619000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119746000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64357000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48042000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	7654000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	5157000	usd
CY2022	us-gaap	Gross Profit GrossProfit	56703000	usd
CY2021	us-gaap	Gross Profit GrossProfit	42885000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52906000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47642000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	82838000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	87535000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-79041000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-92292000	usd
CY2022	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21559000	usd
CY2021	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17291000	usd
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	8438000	usd
CY2021	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	-0	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	1010000	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	212000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108028000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109371000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1755000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1449000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110820000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110820000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-82000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-296000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-109865000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111116000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.81
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.96
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22806812
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22347481
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23113000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-296000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10580000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-82000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110820000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	924000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	831000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	870000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	14007000	usd
CY2021	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	14848000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	498000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-476000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	10580000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23113000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1754000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	893000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	942000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	362000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2868000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	987000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4671000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3626000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4111000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1269000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1020000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	281000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1998000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1309000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2606000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-703000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	47000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1125000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1176000	usd
CY2022	urgn	Increase Decrease In Uncertain Tax Positions IncreaseDecreaseInUncertainTaxPositions	176000	usd
CY2021	urgn	Increase Decrease In Uncertain Tax Positions IncreaseDecreaseInUncertainTaxPositions	125000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87559000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84892000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	63009000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	51898000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2463000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	64323000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	54256000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	254000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	752000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1060000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4069000	usd
CY2022	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	0	usd
CY2021	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	72402000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1511000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	95783000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	160000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	144000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	97134000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72319000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10635000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8504000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45586000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54090000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56221000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45586000	usd
CY2022	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2021	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	81000	usd
CY2022	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	2165000	usd
CY2021	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	-36000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a href="#" id="notes" title="notes"/><span style="text-transform:uppercase;">Note <em style="font: inherit;">1</em>-Business and Nature of Operations</span></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2022	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-transform:uppercase;">Note<i> </i><em style="font: inherit;">2</em><i> </i>– Basis of Presentation</span></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-size: 10pt; margin: 0pt; font-family: Calibri;">The Company has experienced net losses since its inception and has an accumulated deficit of $577.1 million and $467.3 million as of <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation. </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next <em style="font: inherit;">twelve</em> months from the date the financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from Jelmyto product sales and develop UGN-<em style="font: inherit;">102.</em> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company believes that absent sufficient proceeds received from equity, financing, or business development transactions, the Company will <em style="font: inherit;">not</em> have sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these financial statements. Accordingly, the Company will, over the next <em style="font: inherit;">twelve</em> months, require significant additional financing to continue its operations. In addition, there can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, on terms that are satisfactory to the Company, and in amounts sufficient to meet its needs. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Failure to successfully receive additional financing will require the Company to delay, limit or reduce product development and commercialization efforts.</p>
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577100000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467300000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p>
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p>
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2165000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M23D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M15D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1025	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0562	pure
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110820000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22806812
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22347481
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.81
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.96
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	49000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2887000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	360000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2527000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1141000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	357000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	58000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5527000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5786000	usd
CY2022Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	618000	usd
CY2021Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	497000	usd
CY2022Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	2853000	usd
CY2021Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1377000	usd
CY2022Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1285000	usd
CY2021Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1748000	usd
CY2022Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1609000	usd
CY2021Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1965000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	491000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	729000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	938000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	365000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	72000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-153000	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	1010000	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	212000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1556000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4676000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3894000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2019000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1958000	usd
CY2022Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6695000	usd
CY2021Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	5852000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	44663000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	107000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44556000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	45480000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	26000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	45454000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	66882000	usd
CY2021Q4	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Losses Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax	26000	usd
CY2021Q4	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	66856000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	42200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44556000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	66181000	usd
CY2022Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	0	usd
CY2021Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	675000	usd
CY2022Q4	us-gaap	Investments Investments	44556000	usd
CY2021Q4	us-gaap	Investments Investments	66856000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4447000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4193000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3150000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2226000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	900000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	usd
CY2020Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	75000000	usd
CY2021	urgn	Capitalized Closing Costs On Prepaid Forward Obligation CapitalizedClosingCostsOnPrepaidForwardObligation	2599000	usd
CY2021	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17291000	usd
CY2021	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	3979000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
CY2022	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21559000	usd
CY2022	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	8348000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1146000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	904000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	788000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	975000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1045000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	224000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	224000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	65000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	66000	usd
CY2022	us-gaap	Lease Cost LeaseCost	816000	usd
CY2021	us-gaap	Lease Cost LeaseCost	887000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1195000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	251000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	49000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	300000	usd
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	243000	usd
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	251000	usd
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	49000	usd
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	543000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	224000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	224000	usd
CY2020Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	842000	usd
CY2021	urgn	Sales Reserve Accruals SalesReserveAccruals	8239000	usd
CY2021	urgn	Sales Reserve Utilization SalesReserveUtilization	-7767000	usd
CY2021Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1314000	usd
CY2022	urgn	Sales Reserve Accruals SalesReserveAccruals	13430000	usd
CY2022	urgn	Sales Reserve Utilization SalesReserveUtilization	-13307000	usd
CY2022Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1437000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23100000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22500000
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3281494
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1595328
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	410064
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	5.19
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	11.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	593000
CY2021	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	11.92
CY2021	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	22.07
CY2022	urgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedFairValue	2200000	usd
CY2021	urgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedFairValue	7000000.0	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4000000.0	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1449000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	337717
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	39.18
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	496417
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	27.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	800000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	usd
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2590539
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1910065
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	900000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10580000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23113000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	584000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1454000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1171000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-5000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1755000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96434000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77277000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	11485000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10958000	usd
CY2022Q4	urgn	Deferred Tax Assets Issuance Costs DeferredTaxAssetsIssuanceCosts	0	usd
CY2021Q4	urgn	Deferred Tax Assets Issuance Costs DeferredTaxAssetsIssuanceCosts	65000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1489000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1909000	usd
CY2022Q4	urgn	Deferred Tax Assets Rightofuse Asset DeferredTaxAssetsRightofuseAsset	-434000	usd
CY2021Q4	urgn	Deferred Tax Assets Rightofuse Asset DeferredTaxAssetsRightofuseAsset	-228000	usd
CY2022Q4	urgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	461000	usd
CY2021Q4	urgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	282000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1769000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1207000	usd
CY2022Q4	urgn	Deferred Tax Assets Depreciation Of Fixed Assets DeferredTaxAssetsDepreciationOfFixedAssets	-113000	usd
CY2021Q4	urgn	Deferred Tax Assets Depreciation Of Fixed Assets DeferredTaxAssetsDepreciationOfFixedAssets	-158000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	561000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	319000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	129601000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100619000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100619000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	76963000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28982000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	23656000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	129601000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100619000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108028000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109371000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-24847000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25155000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1052000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2264000	usd
CY2022	urgn	Effective Income Tax Rate Reconciliation Tax Credit Research Development And Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditResearchDevelopmentAndOrphanDrugAmount	3586000	usd
CY2021	urgn	Effective Income Tax Rate Reconciliation Tax Credit Research Development And Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditResearchDevelopmentAndOrphanDrugAmount	-0	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-263000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-58000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	176000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	125000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	28982000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	23656000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	241000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	617000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1755000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1449000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13300000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-10100000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	419100000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	335800000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2842000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2717000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	176000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	125000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3018000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2842000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3000000.0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1100000	usd

Files In Submission

Name	View Source	Status
0001437749-23-007710-index-headers.html	Edgar Link	pending
0001437749-23-007710-index.html	Edgar Link	pending
0001437749-23-007710.txt	Edgar Link	pending
0001437749-23-007710-xbrl.zip	Edgar Link	pending
b01.jpg	Edgar Link	pending
b02.jpg	Edgar Link	pending
b03.jpg	Edgar Link	pending
ex_451119.htm	Edgar Link	pending
ex_451120.htm	Edgar Link	pending
ex_451121.htm	Edgar Link	pending
ex_451122.htm	Edgar Link	pending
ex_451123.htm	Edgar Link	pending
ex_451124.htm	Edgar Link	pending
ex_491982.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipelinedec2022.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20221231.xsd	Edgar Link	pending
urgn20221231_10k.htm	Edgar Link	pending
urgn-20221231_cal.xml	Edgar Link	unprocessable
urgn-20221231_def.xml	Edgar Link	unprocessable
urgn-20221231_pre.xml	Edgar Link	unprocessable
urgn-20221231_lab.xml	Edgar Link	unprocessable
urgn20221231_10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2023 Q1 Form 10-K Financial Statement

#000143774923007710 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2023 Q1 Form 10-K Financial Statement

#000143774923007710 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn